To date, we’ve invested over $287.2M in high-risk, high-reward research to accelerate and expand life-saving treatment options. We lead a unique, collaborative, science-focused strategy and have been a driving force in every major advancement in pancreatic cancer research since 1998.<\/p>\n
Progress is paramount. We drive bold, innovative research with the singular mission: transforming pancreatic cancer into a curable disease.<\/p>\n<\/p>\t\t\t \n <\/div>\n\t<\/div><\/div>\n<\/section>\n\n\n\n\n\n\n
Join us on June 25 for a dynamic roundtable discussion exploring cutting-edge strategies to advance cancer immunotherapies \u2014 including promising breakthroughs in cancer vaccines.<\/p>\n <\/div>\n \n For more details, <\/span>Read More \n
Studies referenced are supported by the Lustgarten Foundation\u2019s Robert F. Vizza Clinical Accelerator Initiative (CAI) Cancer immunotherapy is the use of the immune system to prevent or treat cancer. Unlike […]<\/p>\n <\/div>\n \n For more details, <\/span>Read More \n
Federal funding cuts to cancer research are devastating\u2014but we\u2019re not giving up, and neither should you! Know the facts – Why it matters and who it hurts – In moments […]<\/p>\n <\/div>\n \n For more details, <\/span>Read More \n